Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies   KT-621 parallel Phase 2b

KYMR

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Kymera's KT-621 Japanese Phase 1 data supports 2b readouts in 2027

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies   KT-621 parallel Phase 2b</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Kymera reported Phase 1 data for KT-621, its oral STAT6 degrader, in healthy Japanese adults showing rapid, durable STAT6 degradation and a favorable PK profile with strong safety signals. The JDA presentation reinforces KT-621&#039;s translational potential and long-term plan includes parallel Phase 2b trials in atopic dermatitis (mid-2027 data) and asthma (late-2027 data), potentially accelerating late-stage development.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>KT-621 Phase 1 in Japanese adults shows rapid STAT6 degradation.</li><li>PK profile favorable; Day 7 degradation ≥98% at both doses.</li><li>Phase 2b trials in AD and asthma data due mid/late 2027.</li><li>JDA presentation reinforces KT-621 safety and translational potential.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Kymera Therapeutics (KYMR)</strong>: Primary company; KT-621 program data in Japanese trial supports broader Phase 2b/3 trajectory.</li><li><strong>KT-621 (KT-621)</strong>: First-in-class STAT6 degrader; active Phase 2b in AD and asthma.</li><li><strong>Japanese Dermatological Association (JDA)</strong>: Venue for data presentation; no direct market impact but increases visibility.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News; the article reports on ongoing KT-621 clinical development milestones and near-term catalysts (2b data readouts), aligning with industry development updates.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>JDA presentation on June 12, 2026 elevates KT-621 visibility.</li><li>Mid-2027 and late-2027 readouts for AD and asthma are near-term catalysts.</li><li>Phase 1 Japanese results align with prior data, lowering translational risk.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>24 healthy Japanese adults enrolled in Phase 1.</li><li>Two dose levels tested; 7 days of dosing.</li><li>Median degradation ≥98% at Day 7 for both doses.</li><li>Phase 2b readouts: AD mid-2027; asthma late-2027.</li><li>JDA presentation: KT-621 PK/PD and safety data.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish over the next 6-12 months as 2b readouts approach and data de-risk KT-621.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="center"><em>Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies </em></p>  <p align="center"><em>KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively</em></p>  <p>WATERTOWN, Mass., June  12, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=GbCq_qkiZKSYbi2MSgLJkbhsR7mX5Fg6YMnQlpBbYgUtkpigM8wUueqpz4oflvic2AYGzvOD39b5lkXEAWFLw17jMizDSLMxOop05eZ2TuE=" rel="nofollow" target="_blank">Kymera Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/KYMR">KYMR</a>), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the results from the Phase 1 study of KT-621, its first-in-class, oral STAT6 degrader, in healthy Japanese adults were shared in an oral presentation at the Japanese Dermatological Association (JDA) Annual Meeting being held June 11-14, 2026, in Kyoto, Japan.</p>  <p>"The consistency we've demonstrated across KT-621 Phase 1 studies, from robust STAT6 degradation to a favorable safety profile, reflects the strong fidelity of translation of this unique approach from preclinical to clinical settings and further highlights KT-621's compelling profile," said Jared Gollob, MD, Chief Medical Officer of Kymera Therapeutics. "We believe KT-621 has the potential to transform care through a truly novel oral treatment option for patients living with chronic Type 2 inflammatory conditions, and the data reported to date continue to support its advancement globally across multiple diseases, starting with atopic dermatitis and asthma."</p>  <p>The Company has previously reported positive Phase 1 data for KT-621 in non-Japanese healthy volunteers and patients with moderate to severe atopic dermatitis. Across these studies, KT-621 demonstrated rapid, deep and sustained STAT6 degradation in blood and skin, robust reductions in disease-relevant Type 2 inflammatory biomarkers, meaningful improvements on clinical endpoints and patient-reported outcomes in atopic dermatitis as well as in comorbid asthma and allergic rhinitis, and a favorable safety profile.</p>  <p>The Phase 1 trial in healthy Japanese adults was designed to provide the pharmacokinetic/pharmacodynamic (PK/PD) and safety data required by regulators prior to enrollment of patients in Japan in the global KT-621 Phase 2b studies. The randomized, double-blind, placebo-controlled Phase 1 study enrolled 24 healthy Japanese adults across two dose levels randomized 3:1 to receive KT-621 or placebo once daily for seven days. KT-621 demonstrated a favorable PK profile, including rapid absorption and dose-proportional increases in plasma exposure, and rapid, sustained STAT6 degradation in blood, with median degradation ≥98% at both dose levels at Day 7. KT-621 was well tolerated with a favorable safety profile across both doses. Overall, these results in healthy Japanese adults were comparable to those observed in non-Japanese adults and atopic dermatitis patients, further supporting KT-621's potential as a novel oral approach for chronic Type 2 inflammatory diseases.</p>  <p>The parallel KT-621 Phase 2b trials in <a href="https://www.globenewswire.com/Tracker?data=DyOO6aSs-ZZIb3dJleC3vv4r7Be8a-6L3dycO805vSxT7GiwZbpfp2gU-w5uMxfL0pyAo5EqgSSS80V8NqhUILL1Cwrp52iw63IpmWDseWxCCnF0JyI7fR8n5aP6jLqd" rel="nofollow" target="_blank">atopic dermatitis and asthma</a> are ongoing, with data expected by mid-2027 and late 2027, respectively. These studies are intended to accelerate KT-621 development for subsequent parallel Phase 3 registration studies across multiple Type 2 inflammatory diseases.</p>  <p><strong>Japanese Dermatological Association (JDA) Annual Meeting </strong></p>  <ul type="disc"><li>Title: KT-621, an Oral, Once Daily STAT6 Degrader: PK, PD and Safety in Healthy Japanese Adults</li><li>Type/Session: Oral Presentation, Inflammatory Disease</li><li>Speaker: Sagar Agarwal, PhD, Vice President, Clinical Pharmacology, Kymera Therapeutics</li><li>Date/Time: Friday, June 12, 2026, at 10:10 am JST</li></ul>  <p>A copy of the JDA presentation will be available in the <a href="https://www.globenewswire.com/Tracker?data=c4Uzm8RsAZbiTu_jXRpOMbKydYx2IK-cSAdfHXNxx8ceFNFoH9mClZ5XrCwLkXgKzcdDflbkwcrg5ZYUGDU_PDUHKobb5trUR-LRAt0te2VPD-xeaPrzabvfk5Gz_QnwPZuG5mvQ6ejCugtDC7k5RgNbrrUe2IM_g90Oxtwhs1o=" rel="nofollow" target="_blank">Resource Library</a> section of Kymera&#39;s website.</p>  <p><strong>About KT-621 </strong><br></br>KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is currently in Phase 2 clinical testing in <a href="https://www.globenewswire.com/Tracker?data=DyOO6aSs-ZZIb3dJleC3vnNpcxU81M8jOr-2s6jru0yWURvxA-kbezRc93SBUpN9aDxEcFchkpqsqP8jb9T6dEKSpL98HPuOg10_j8fev2lYmkfeYL4HGwMu1tM1t2uJ" rel="nofollow" target="_blank">atopic dermatitis (AD) and asthma</a>. In the Phase 1 clinical study in AD patients, KT-621 demonstrated deep STAT6 degradation in blood and skin, robust reductions in disease-relevant Type 2 inflammatory biomarkers, meaningful improvements on clinical endpoints and patient-reported outcomes in AD and comorbid asthma and allergic rhinitis, and was well tolerated with a favorable safety profile. KT-621, the first STAT6-directed drug to enter clinical evaluation, has the potential to transform treatment for more than 140 million patients around the world living with Type 2 inflammatory diseases such as AD, asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), and bullous pemphigoid (BP), among others.</p>  <p><strong>About Kymera Therapeutics</strong><br></br>Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston's top workplaces for the past several years. For more information about our science, pipeline and people, please visit <a href="https://www.globenewswire.com/Tracker?data=_yUAKu9DhuaPLFiGdlcYb2TJ-yXAi-z1wHNY4_SxM4HA6h0ibnOaJpzSPmiBCq2BYA1feMuA3otzk6qfMEnTPRru0w6azyBM3K5PRR5A0fU=" rel="nofollow" target="_blank">www.kymeratx.com</a> or follow us on <a href="https://www.globenewswire.com/Tracker?data=fIm9DmvB0ACLSipH7tVYqmQ4vPGYMlCPu4m5Yz4SE0JumHOstuBsLkBAXF2lzFCtk6Hk2IlAxdHFzy-l33SR7A==" rel="nofollow" target="_blank">X</a> or <a href="https://www.globenewswire.com/Tracker?data=l7ieIaUvgq6xrXN1vBdAgS1XvQxWT458STBBMK0dx99RkNOF5gFkgK0yu9lccuVbJchQM40S7tWQLgBfT6nF8chnHWEqXBbMijfyFk2QetpoFSemt2jGjYHyRt2MzNTc" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p><strong>Cautionary Note Regarding Forward-Looking Statements</strong><br></br>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding strategy, business plans and objectives on the development of KT-621, including the therapeutic potential, clinical benefits and safety thereof, the Phase 1b results providing further validation of KT-621 in AD and the potential clinical benefits of KT-621 in dermatology, gastroenterology and respiratory indications, the effect of initial parallel development of Phase 2b studies in AD and asthma patients on acceleration of late parallel development and dose selection across multiple indications, Phase 2b data readout of KT-621 in patients with moderate to severe AD expected by mid-2027. The words &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;could,&#34; &#34;would,&#34; &#34;should,&#34; &#34;expect,&#34; &#34;plan,&#34; &#34;anticipate,&#34; &#34;intend,&#34; &#34;believe,&#34; &#34;expect,&#34; &#34;estimate,&#34; &#34;seek,&#34; &#34;predict,&#34; &#34;future,&#34; &#34;project,&#34; &#34;potential,&#34; &#34;continue,&#34; &#34;target,&#34; "upcoming" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management&#39;s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: that the results from the Phase 2b KT-621 trial may differ from the Phase 1/1b KT-621 data, that preclinical and clinical data, including the results from the Phase 1/1b trial of KT-621, is not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate, uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with and submissions to regulatory authorities, the availability of funding sufficient for our operating expenses and capital expenditure requirements and other factors. These risks and uncertainties are described in greater detail in the section entitled &#34;Risk Factors&#34; in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the SEC. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.</p>  <p><strong>Investor Contact:</strong> <br></br>Justine Koenigsberg<br></br><a href="https://www.globenewswire.com/Tracker?data=4dgtwt_4CtTWBJNHUz4ibHTaRCzEUJNuKe0Y_hk5D0EDKPlEXKSOX1LjX7J-sy8o8S8ucPLdens8wQlr1QOs3_RBfyKtbwlaoi0ZsIV63WA=" rel="nofollow" target="_blank">investors@kymeratx.com</a><br></br>857-285-5300 </p>  <p><strong>Media Contact: </strong><br></br>Bridgette Chandhoke<br></br><a href="https://www.globenewswire.com/Tracker?data=66eiIS8oFo7SR0oKeoh0M6ZLnrk-TiDc0Y-CZCN3Eid59Y6nOPdJl6_8-eNUpOuh8AdyC24aRA9HNwnDfzXg2SdNkm144X9Lr_nimtuOXG4=" rel="nofollow" target="_blank">media@kymeratx.com</a> <br></br>857-285-5300</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc0NTkwMSM3NjU4NTM1IzIyMDA4MzI="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NWI1YTc2NGYtYTIwMi00NDQ2LWJhZTMtMDRlOTJjYmViNWY3LTEyMTIzODUtMjAyNi0wNi0xMi1lbg==/tiny/Kymera-Therapeutics-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/4d3d3283-c57d-401e-9e1b-53f17e22d76b"><img src="https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png" border="0" width="150" height="35" alt="Primary Logo"></img></a></p>

Kymera reported Phase 1 data for KT-621, its oral STAT6 degrader, in healthy Japanese adults showing rapid, durable STAT6 degradation and a favorable PK profile with strong safety signals. The JDA presentation reinforces KT-621's translational potential and long-term plan includes parallel Phase 2b trials in atopic dermatitis (mid-2027 data) and asthma (late-2027 data), potentially accelerating late-stage development.

kymera-therapeutics-presents-phase-1-data-in-healthy-japanese-adults-for-kt-621-a-first-in-class-oral-stat6-degrader-at-the-japanese-dermatological-association-annual-meeting

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News